Você está na página 1de 5


Eleftherios Gkioulekas
Professor of Mathematics
Undergraduate Program Coordinator
The University of Texas -- Rio Grande Valley
School of Mathematical and Statistical Sciences
1201 West University Drive
Edinburg, TX 78539-2909
July 9, 2021

Letter of Support for Professor Paolo Marinho De Andrade Zanotto

Dean Vahan Agopyan and Distinguished Professors,

I am writing to you in support of Dr. Paolo Zanotto, his advocacy of early outpatient treatment for Covid-
19, and the need for caution with the deployment of the current generation of Covid vaccines. Dr. Zanotto
is a very accomplished scholar and researcher. I know him via the C19 group, an ad hoc think tank of more
than 1000 medical doctors, academics, lawyers, and investigative journalists, who are focused on
researching covid treatments, vaccine safety, and promoting patient advocacy and medical freedom.
Myself, I have been trained in Applied Mathematics at the California Institute of Technology where I earned
my B.Sc. degree and the University of Washington, where I earned my M.S. and Ph.D. degree. I have
published in the areas of hydrodynamic turbulence, atmospheric science, foundations of quantum
mechanics, and mathematics education. Having done diverse work in the past, with the pandemic crisis, I
have not been afraid to put ongoing projects on hold to learn the medical literature on early treatments and
to contribute a statistical reanalysis methodology of existing observational studies.

In short, I noticed that we had strong evidence of the effectiveness of early outpatient treatment as early as
April 28, 2020 when Dr. Zelenko reported1 treating 1450 patients, of which 405 patients were classified as
high risk and given the triple drug therapy (hydroxychloroquine, azithromycin, zinc sulfate), with endpoint
outcomes 2 deaths and 6 hospitalizations. The observed treated high risk patient mortality rate 0.4% should
be contrasted with the United States CFR, which ranged from 2% to 6%2 during that time period and with
the mortality rate statistics for high risk patients, which typically range from 5% to 10% but can extend
from 3% to 20% depending on the demographic distribution3. According to my independent statistical

V. Zelenko, To all medical professionals around the world [letter]., April 28, 2020. Available at:
https://tinyurl.com/yxk8ssco. Accessed November 26, 2020, now censored by Google. Available at:
Case fatality rate data: https://ourworldindata.org/mortality-risk-covid#the-case-fatality-rate
Epidemiology Group of Emergency Response Mechanism of New Coronavirus Pneumonia, Chinese Center for
Disease Control and Prevention. "Analysis of Epidemiological Characteristics of New Coronavirus Pneumonia",
Chinese Journal of Epidemiology 41 (2020), 145-151.
Graziano Onder, Giovanni Rezza, Silvio Brusaferro: "Case-Fatality Rate and Characteristics of Patients Dying in
Relation to COVID-19 in Italy", JAMA 323 (2020), 1775-1776
R. Verity and L.C. Okell and I. Dorigatti and P. Winskill and C. Whittaker and N. Imai and G. Cuomo-Dannenburg
and H. Thompson and P.G.T. Walker and H. Fu and A. Dighe and J.T. Griffin and M. Baguelin and S. Bhatia and A.
Boonyasiri and A. Cori and Z. Cucunuba and R. FitzJohn and K. Gaythorpe and W. Green and A. Hamlet and W.
Hinsley and D. Laydon and G. Nedjati-Gilani and S. Riley and S. van Elsland and E. Volz and H. Wang and Y.
Wang and X. Xi and C.A. Donnelly and A.C. Ghani and N.M. Ferguson: "Estimates of the severity of coronavirus
disease 2019: a model-based analysis", Lancet Infect Dis 20 (2020), 669-677
School of Mathematical & Statistical Sciences

MAGC 3.202 LHSB 2.500A utrgv.edu

1201 West University Drive One West University Blvd.
Edinburg, Texas 78539-2999 Brownsville, Texas 78520-4933
(956) 665-3452 (956) 882-7831
analysis4, there is a clear unambiguous efficacy signal that Zelenko's protocol works based solely on what
was known, as of April 28 2020, if the untreated high risk patient mortality rate exceeds a 1.7% efficacy
threshold, which it does and by a very wide margin. This alone was sufficient evidence to justify an
emergency adoption of Zelenko's protocol as a baseline standard of care as early as April 29, 2020.
Furthermore, a comparison of Dr. Zelenko's June report5 (800 high risk patients with 2 deaths) compared
against the 3.4% mortality rate reported in his control group6 (377 low and high risk patients with 13 deaths)
and the 3.4% mortality rate of a demographically similar control group in Israel7 (4179 low and high risk
patients with 143 deaths), suggests a minimum of 92% efficacy that is statistically significant, relative to
the therapeutic nihilism promoted by the NIH and WHO. Unfortunately, malfeasance within the US
government and academia has undermined Dr. Zelenko's efforts8. Brazil was one of several early-adopter
nations that made the right decision to adopt Dr. Zelenko's early treatment protocol as early as April/May

Dr. Zelenko's protocol has since evolved9 to a sequenced multidrug therapy for handling Covid-19
successfully via at home treatment. The latest study from France10 (1495 treated high risk patients older
than 60 with 5 deaths) allows lowering the efficacy threshold, with respect to high risk patient mortality

E. Gkioulekas: On the Zelenko protocol: The road not taken,
V. Zelenko. "To Dr. Moshe Bar Siman Tov" [letter], June 14, 2020. Available at: https://tinyurl.com/y4hw7dye.
Accessed November 26, 2020, now censored by Google. Available at:
https://faculty.utrgv.edu/eleftherios.gkioulekas/zelenko/Zelenko-memo-June-Dr-Shemtov-letter.pdf. Accessed
November 26, 2020.
M. Scholz, R. Derwand, V. Zelenko. "COVID-19 outpatients - early risk-stratified treatment with zinc plus low
dose hydroxychloroquine and azithromycin: a retrospective case series study", International Journal of
Antimicrobial Agents 56 (2020), 106214
N. Barda, D. Riesel, A. Akriv, J. Levy, U. Finkel, G. Yona, D. Greenfeld, S. Sheiba, J. Somer, E. Bachmat, G.N.
Rothblum, U. Shalit, D. Netzer, R. Balicer, Noa Dagan. "Developing a COVID-19 mortality risk prediction model
when individual-level data are not available", Nature Communications 11 (2020), 4439
Steven Hatfill, "How a Single Point Failure Destroyed the National Pandemic Plan", April 2021,
Peter A. McCullough, Paul E. Alexander, Robin Armstrong, Cristian Arvinte, Alan F. Bain, Richard P. Bartlett,
Robert L. Berkowitz, Andrew C. Berry, Thomas J. Borody, Joseph H. Brewer, Adam M. Brufsky, Teryn Clarke,
Roland Derwand, Alieta Eck, John Eck, Richard A. Eisner, George C. Fareed, Angelina Farella, Silvia N. S.
Fonseca, Charles E. Geyer, Jr., Russell S. Gonnering, Karladine E. Graves, Kenneth B. V. Gross, Sabine Hazan,
Kristin S. Held, H. Thomas Hight, Stella Immanuel, Michael M. Jacobs, Joseph A. Ladapo, Lionel H. Lee, John
Littell, Ivette Lozano, Harpal S. Mangat, Ben Marble, John E. McKinnon, Lee D. Merritt, Jane M. Orient, Ramin
Oskoui, Donald C. Pompan, Brian C. Procter, Chad Prodromos, Juliana Cepelowicz Rajter, Jean-Jacques Rajter, C.
Venkata S. Ram, Salete S. Rios, Harvey A. Risch, Michael J. A. Robb, Molly Rutherford, Martin Scholz, Marilyn
M. Singleton, James A. Tumlin, Brian M. Tyson, Richard G. Urso, Kelly Victory, Elizabeth Lee Vliet, Craig M.
Wax, Alexandre G. Wolkoff, Vicki Wooll, Vladimir Zelenko."Multifaceted highly targeted sequential multidrug
treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19)", Reviews in Cardiovascular Medicine
21 (4) (2020), 517-530
Matthieu Million, Jean-Christophe Lagier, Herve Tissot-DuPont, Isabelle Ravaux, Catherine Dhiver, Christelle
Tomei, Nadim Cassir, Lea DeLorme, Sebastien Cortaredona, Stephanie Gentile, Elisabeth Jouve, Audrey Giraud-
Gatineau, Herve Chaudet, Laurence Camoin-Jau, Philippe Colson, Philippe Gautret, Pierre-Edouard Fournier,
Baptiste Maille, Jean-Claude Deharo, Paul Habert, Jean-Yves Gaubert, Alexis Jacquier, Stephane Honore, Katell
Guillon-Lorvellec, Yolande Obadia, Philippe Parola, Philippe Brouqui, Didier Raoult, IHU COVID-19 Task Force.
"Early Treatment with Hydroxychloroquine and Azithromycin in 10,429 COVID-19 Outpatients: A Monocentric
Retrospective Cohort Study", IHU Preprint, Retrieved on 05/28/2021 from https://www.mediterranee-
School of Mathematical & Statistical Sciences

MAGC 3.202 LHSB 2.500A utrgv.edu

1201 West University Drive One West University Blvd.
Edinburg, Texas 78539-2999 Brownsville, Texas 78520-4933
(956) 665-3452 (956) 882-7831
rate reduction from 1.7% down to 0.79%11. and has shown similar 0.3% mortality rate for treated high risk
patients as Dr. Zelenko1, which is also consistent with Dr. Procter's study12 (320 treated high risk patients
with 1 death) where a similar 0.3% mortality rate has been observed. In all three cases, a sequenced
multidrug approach has been used, with consistent mortality rate outcomes between 3 different doctors, in
different locations, treating different high-risk patient demographics. This could have been improved upon
by another factor of approximately 10 via a national campaign to provide ivermectin and
hydroxychloroquine prophylaxis to the entire high risk population, as an alternative to vaccination as early
as May 17, 202013. Additional strong evidence in support of early treatment are available from Iran14 and
Saudi Arabia15. Dr. Risch's expert testimony16 as well as the research presentations by Dr. Risch17 and Dr.
McCullough18 also give a good overview of the current state of research on early treatment and its efficacy.

I share Dr. Zanotto's concerns with respect to the current generation of mRNA and adenovirus vaccines. In
the United States, VAERS reports more than 6000 deaths associated with these vaccines19. The incident
distribution with respect to onset interval20 strongly indicates a causal relation. Due to underreporting, we
are most likely looking at 60000 deaths, which corresponds to 1 death by vaccine for every 10 covid deaths
in the United States, throughout the entire pandemic, averaged over the entire pandemic and all age groups.
With a hypothetical 100% vaccination rate, I estimate that we will see in the United States approximately
1 vaccine death for every 5 covid deaths.

E. Gkioulekas: Update concerning Dr. Didier Raoult's latest paper, [research presentation],
Brian C. Procter, Casey Ross, Vanessa Pickard, Erica Smith, Cortney Hanson, Peter A. McCullough. "Clinical
outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection", Reviews in
Cardiovascular Medicine 21 (4) (2020), 611-614
V. Zelenko. "Update on the efficacy of adding zinc to the hydroxychloroquine treatment". Part 1. [interview],
05/17/2020, https://www.bitchute.com/video/nQhNX00PMXc8/
Mokhtari M, Mohraz M, Mehdi Gouya M, Namdari Tabar H, Tayeri K, Aghamohamadi S, Rajabpoor Z, Karami
M, Raeisi A, Rahmani H, Khalili H. "Clinical outcomes of patients with mild COVID-19 following treatment with
hydroxychloroquine in an outpatient setting" Int Immunopharmacol. 2021 Apr . PMCID: PMC8023208.
Tarek Sulaiman, Abdulrhman Mohana, Laila Alawdah, Nagla Mahmoud, Mustafa Hassanein, Tariq Wani, Amel
Alfaifi, Eissa Alenazi, Nashwa Radwan, Nasser AlKhalifah, Ehab Elkady, Manwer Alanazi, Mohammed Alqahtani,
Khalid Abdullah, Yousif Yousif, Fouad AboGazalah, Fuad Awwad, Khaled Alabdulkareem, Fahad AlGhofaili,
Ahmad AlJedai, Hani Jokhdar, Fahad Alrabiah. "The Effect of Early Hydroxychloroquine-based Therapy in
COVID-19 Patients in Ambulatory Care Settings: A Nationwide Prospective Cohort Study", medRxiv
2020.09.09.20184143; doi: https://doi.org/10.1101/2020.09.09.20184143
H.A. Risch. "Hydroxychloroquine in Early Treatment of High-Risk COVID-19 Outpatients: Efficacy and Safety
Evidence", Expert testimony for Adamson Skelly Vs ROA case, https://weareallessential.ca/wp-
H.A. Risch: "Hydroxychloroquine and its friends", [research presentation], https://rumble.com/vj4pop-
P.A. McCullough: Pathophysiologic Basis and Clinical Rationale for Early Ambulatory Treatment for COVID-19
and Update on Vaccine Safety, [research presentation], https://rumble.com/vji3dj-peter-a.-mccullough-seminar-at-


School of Mathematical & Statistical Sciences

MAGC 3.202 LHSB 2.500A utrgv.edu

1201 West University Drive One West University Blvd.
Edinburg, Texas 78539-2999 Brownsville, Texas 78520-4933
(956) 665-3452 (956) 882-7831
Brazil needs to go its own way. Your scientists need academic freedom to openly debate these issues, so
that decisions are made based on science that benefit your people and not pharmaceutical companies with
vested interests in vaccines or expensive drugs. Personally I have refused to take the current experimental
vaccines and I am using instead hydroxychloroquine and zinc prophylactically. I am hoping the new
Novavax vaccine will prove to be a safer alternative to the unsafe first generation mRNA and adenovirus
covid injections. The existing prophylaxis option via hydroxychloroquine or ivermectin makes it possible
to take the time to try to develop a truly safe and effective vaccine.

To that end, I strongly recommend that you support the academic freedom of scientists like Dr. Paolo
Zannoto and support him as he is under attack by corporate and political interests that do not have the best
interests of the Brazilian people in mind. As Dean, your best option is to remain neutral and commit to
supporting the academic freedom of all your faculty, including Dr. Zanotto. I also urge Dr. Zanotto's
colleagues to realize that they have to stand up and protect his academic freedom, because doing so will
protect their academic freedom on other issues that may emerge in the future, where they find it necessary
to take a controversial position. We are entering a turbulent unstable period at a global level that will
intensify and will confront many of us with many such challenges in the years ahead.

I am available to answer questions. I also recommend that you take the time to watch during your meetings
the research presentations by Dr. Harvey Risch17 and Dr. Peter McCullough18.

Yours sincerely,

Eleftherios Gkioulekas, Ph.D.

ps: The opinions expressed are my own and not those of my institution.

Endorsed by:
Dr. Vladimir Zev Zelenko, MD, Board Certified Family Physician,

Paul E. Alexander, PhD,

Health Research Methodologist
Evidence-Based Medicine Clinical epidemiologist
Former WHO-PAHO and US Health and Human Services (HHS) consultant/senior COVID
Pandemic advisor

H. C. Tenenbaum DDS, Dip. Perio., PhD, FRCD(C);

Professor of Periodontology, Faculty of Dentistry, University of Toronto
Professor of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto
Professor of Periodontology, School of Dental Medicine, Tel Aviv University, Israel
School of Mathematical & Statistical Sciences

MAGC 3.202 LHSB 2.500A utrgv.edu

1201 West University Drive One West University Blvd.
Edinburg, Texas 78539-2999 Brownsville, Texas 78520-4933
(956) 665-3452 (956) 882-7831
André Fini Terçarolli <andre@advpimentel.com.br>,
Bruno Franchi Theophilo <brunoftheophilo@yahoo.com.br>,
Bruno Theófilo <bftheophilo@gmail.com>,
Carlos Taborda <taborda@usp.br>,
David Wiseman <synechion@aol.com>,
Edison Durigon <eldurigo@usp.br>,
Francisco Nobrega <francisco.nobrega@gmail.com>,
Gustavo Amarante-Mendes <gpam@usp.br>,
Jorge Kalil <jkalil@usp.br>,
Luis Carlos de Souza Ferreira <lcsf@usp.br>,
Maurício Pazini Brandão <pazinibrandao@gmail.com>,
Osmar Serraglio <osmar@osmarserraglio.com>,
Paolo Zanotto <pzanotto@usp.br>,
Patricia Gama <patgama@usp.br>,
Paulo Saldiva <pepino@usp.br>,
Péricles Prade <pericles2@pradeprade.adv.br>,
Peter A. McCullough <peteramccullough@gmail.com>,
Regina Scivoletto <rscivole.rs@gmail.com>,
Secretaria ICB <icbsedir@icb.usp.br>,
Vahan Agopyan <vahan.agopyan@usp.br>,
Wothan Tavares <wtavares@usp.br>,
Tenenbaum, Howard <Howard.Tenenbaum@sinaihealth.ca>,
Paul Elias Alexander <elias98_99@yahoo.com>,
Zelenko Family <zz613@hotmail.com>

School of Mathematical & Statistical Sciences

MAGC 3.202 LHSB 2.500A utrgv.edu

1201 West University Drive One West University Blvd.
Edinburg, Texas 78539-2999 Brownsville, Texas 78520-4933
(956) 665-3452 (956) 882-7831